Immunoglobulin E (IgE), though the least abundant human immunoglobulin isotype, drives allergic disease through high-affinity FcεRI binding on mast cells and basophils. Characterizing the IgE antibody repertoire—its diversity, specificity, clonality, and affinity maturation—has become central to understanding allergy pathogenesis and guiding precision immunotherapy. To support this research, we provide flexible and reliable analysis services using protein array technology, meeting diverse needs in cytokine profiling, allergen-specific IgE detection, and biomarker discovery. This review synthesizes current knowledge of the generation, molecular features, and clinical implications of the IgE repertoire, and discusses how repertoire-level insights are reshaping the diagnosis and mechanistic understanding of allergic disease.
Introduction
Allergic diseases—including allergic rhinitis, asthma, atopic dermatitis, food allergy, and anaphylaxis—affect more than a quarter of the global population, and their prevalence continues to rise, particularly in industrialized regions. The unifying immunological hallmark of these conditions is the generation of allergen-specific IgE antibodies through class-switch recombination and somatic hypermutation in B cells, followed by sensitization of tissue-resident mast cells. The classical model of T-helper type 2 (Th2) polarization emphasizes the role of IL-4 and IL-13 in driving this class switch, yet it does not fully explain why some individuals develop broad, polysensitized IgE repertoires while others remain monosensitized to a single allergen source, nor why some sensitized individuals mount clinical reactions upon exposure while others remain clinically tolerant.
These clinical paradoxes have motivated a shift in perspective—from measuring total or single-allergen IgE levels to interrogating the entire IgE antibody repertoire at a molecular level. Repertoire-level analysis integrates information on clonality, epitope specificity, affinity maturation, and the glycosylation status of IgE, providing a more nuanced picture of the humoral allergic response. Such insights are increasingly relevant for the rational design of allergen immunotherapy, the prediction of treatment efficacy, and the identification of biomarkers that distinguish sensitization from symptomatic allergy.
Figure 1. A model for the generation of IgE+ memory B cells. (Source: Akdis M, et al. 2012)
Molecular Foundations of the IgE Repertoire
The human IgE repertoire is generated through the same V(D)J recombination and somatic hypermutation processes that shape other antibody isotypes, but it carries several distinctive features. IgE-encoding transcripts arise from a dedicated constant region gene located downstream of Cγ and Cα in the immunoglobulin heavy chain locus. Sequential class-switching events—first to IgG intermediates and subsequently to IgE—leave characteristic footprints in the surrounding switch regions, allowing molecular tracing of the clonal history of IgE-producing B cells.
Single-cell sequencing studies have revealed that the circulating IgE repertoire in allergic individuals is characterized by relatively low clonal diversity, high somatic hypermutation loads, and a clonally related memory B-cell compartment. Notably, IgE-lineage B cells display shorter lifespans than IgG memory B cells, a feature attributed to the limited survival signals provided by the local tissue microenvironment and the strong pro-apoptotic effect of FcεRI crosslinking in the absence of continuous antigen exposure. This peculiarity has practical consequences: direct sampling of IgE-producing cells is challenging, and the secreted IgE pool detected in serum predominantly reflects the recent output of plasmablasts rather than a stable, archive-like memory compartment.
Affinity maturation within the IgE lineage is also constrained. Because the germinal center reactions that support iterative rounds of mutation and selection appear to occur primarily in IgG-bearing B cells, with subsequent switching to IgE, the affinity of serum IgE often reflects the maturation history of upstream IgG clones. This sequential maturation model helps explain why high-affinity IgE tends to dominate the allergic response and why some allergen-specific IgE clones exhibit extensive somatic hypermutation despite the short lifespan of IgE-secreting cells.
Figure 2. The role of FcεRIβ in mast cell signaling pathways. (Source: Arthur GK, et al. 2022)
Component-Resolved Diagnostics and the Dissection of Allergen-Specific IgE
Traditional allergy diagnostics rely on whole-allergen extracts that contain a complex mixture of allergenic and non-allergenic components. While useful for first-line screening, extract-based assays cannot resolve whether a positive result reflects genuine sensitization to a clinically relevant component or merely cross-reactive antibody binding to homologous, often clinically irrelevant, pan-allergens such as profilins, polcalcins, or cross-reactive carbohydrate determinants. Component-resolved diagnostics (CRD) addresses this limitation by using purified or recombinant single allergens, either individually or in microarray format, to define the fine specificity of the IgE response.
CRD studies have demonstrated that the molecular spreading of IgE sensitization—starting from a limited number of "initiator" allergens and progressively broadening to multiple components within the same allergen source—is a common pattern associated with disease persistence and severity. In grass pollen allergy, expansion from Phl p 1 to Phl p 5 and Phl p 7/12 is associated with symptom persistence, while in peanut allergy, the presence of IgE against Ara h 2 is a strong predictor of clinical reactivity, distinguishing true allergy from asymptomatic cross-sensitization driven by homologous seed storage proteins.
More recently, high-density peptide arrays and phage-display libraries have enabled epitope-level resolution of the IgE repertoire. By mapping continuous and conformational B-cell epitopes recognized by patient IgE, these approaches permit the identification of immunodominant regions, the discovery of cross-reactive epitopes shared across allergen sources, and the design of hypoallergenic variants that retain T-cell reactivity but abolish IgE binding—a cornerstone of modern peptide-based allergen immunotherapy.
Clonal Dynamics and the Relationship Between IgE Repertoire and Clinical Phenotype
Deep sequencing of the IgE heavy chain repertoire has begun to reveal striking associations between clonal architecture and clinical phenotype. Patients with severe, polysensitized atopic dermatitis or multi-food allergy often harbor highly expanded IgE clonotypes with convergent VH gene usage, suggesting a recurrent, antigen-driven selection process. In contrast, individuals with mild seasonal rhinitis tend to display more diverse, lower-frequency IgE clonotypes, consistent with a less skewed, more polyclonal response.
Longitudinal studies have shown that the IgE repertoire is remarkably dynamic in early childhood, evolving in parallel with the atopic march. Infants who develop IgE against a single component, such as the egg allergen Gal d 1 (ovomucoid), and who subsequently fail to outgrow this sensitization, often display progressive broadening of the IgE repertoire to additional ovomucoid epitopes, a pattern that correlates with the persistence of clinical egg allergy. Conversely, children who develop transient IgE responses tend to have low-affinity, low-clonality repertoires that wane with age, supporting the concept that affinity maturation within the IgE lineage is a key determinant of clinical durability.
These observations have important therapeutic implications. The efficacy of allergen immunotherapy correlates with the induction of IgG and IgA antibodies that compete with IgE for allergen binding, blocking mast cell activation. Repertoire-level analysis has shown that successful immunotherapy is accompanied by a shift in the IgE clonal landscape—not necessarily a reduction in total IgE levels, but a redistribution of clonotype frequencies, with the disappearance of dominant high-affinity clones and the persistence of low-affinity, less pathogenic ones. This nuanced dynamic is largely invisible to conventional serology but can be captured by repertoire sequencing and high-resolution CRD.
The Repertoire Perspective on IgE Glycosylation and Effector Function
Beyond sequence and specificity, the biological activity of IgE is profoundly influenced by the glycan structures attached to its constant region. IgE carries N-linked glycans at conserved sites within Cε2 and Cε3, and the composition of these glycans—particularly the degree of sialylation and fucosylation—modulates its binding kinetics to FcεRI, its ability to engage the low-affinity receptor FcεRII (CD23), and its half-life in circulation. Recent glycoproteomic studies have demonstrated that allergen-specific IgE in symptomatic patients tends to be enriched in sialylated glycoforms that enhance basophil activation, whereas the IgE of sensitized but clinically tolerant individuals often displays distinct glycan signatures.
The integration of glycan-level data with repertoire sequencing is opening a new dimension in allergy biomarker discovery. Multiplexed protein arrays that simultaneously capture allergen specificity, IgE concentration, and glycosylation state are being developed, and they hold considerable promise for refining the distinction between sensitization and clinical allergy.
Frequently Asked Questions (FAQs)
The IgE antibody repertoire refers to the full set of allergen-specific IgE molecules circulating in an individual, including their clonal identities, epitope specificities, affinity maturation status, and glycosylation patterns. Because even minute amounts of IgE can sensitize effector cells, the qualitative features of the repertoire often determine clinical phenotype more accurately than total IgE measurements. Repertoire-level analysis therefore provides a molecular fingerprint of the allergic response that can guide diagnosis, prognosis, and immunotherapy decisions.
Modern repertoire profiling combines several complementary approaches. Recombinant or purified single-allergen components, arrayed on planar or bead-based protein arrays, define IgE specificity at component resolution. High-throughput B-cell receptor sequencing of IgE-transcribing cells reveals clonal architecture, somatic hypermutation, and lineage relationships. Mass spectrometry-based glycoproteomics adds a layer of information on glycan structures that modulate effector function. Together, these technologies transform IgE from a single serological marker into a multidimensional analytical readout.
Successful immunotherapy is associated with a shift in the IgE clonal landscape rather than a simple reduction in total IgE. Dominant high-affinity clones tend to decline, while low-affinity, less pathogenic clones persist, accompanied by a rise in blocking IgG and IgA antibodies. Tracking these changes by repertoire sequencing or high-resolution component-resolved testing provides pharmacodynamic biomarkers that can predict treatment response, guide dose adjustment, and identify candidates most likely to achieve durable tolerance.
Yes. Protein arrays are particularly well suited to IgE repertoire research because they enable parallel, quantitative measurement of dozens to hundreds of allergen components, cytokines, and inflammatory mediators from minimal sample volumes. The same platform can be configured for component-resolved diagnostics, epitope mapping with synthetic peptides, or multiplexed cytokine profiling, allowing researchers to integrate allergen specificity with Th1/Th2 effector signatures in a single workflow. This flexibility makes protein arrays a practical bridge between discovery research and translational allergy studies.
Key challenges include the scarcity of circulating IgE-producing B cells, which limits direct repertoire sequencing; the lack of fully standardized reference reagents for many recombinant allergens; incomplete understanding of how glycosylation and other post-translational modifications alter IgE effector function in vivo; and limited integration of repertoire data with clinical outcomes in large prospective cohorts. Ongoing improvements in single-cell technologies, glycoproteomics, and computational analysis are steadily addressing each of these bottlenecks.
References
- Akdis M, et al. IgE class switching and cellular memory. Nat Immunol. 2012 Mar 19;13(4):312-4.
- Arthur GK, et al. Regulation of Trafficking and Signaling of the High Affinity IgE Receptor by FcεRIβ and the Potential Impact of FcεRIβ Splicing in Allergic Inflammation. Int J Mol Sci. 2022 Jan 12;23(2):788.
- Gould HJ, et al. IgE in allergy and asthma today. Nat Rev Immunol. 2008 Mar;8(3):205-17.
- Croote D, et al. High-affinity allergen-specific human antibodies cloned from single IgE B cell transcriptomes. Science. 2018 Dec 14;362(6420):1306-1309.
- Croote D, Wong JJW, Pecalvel C, Leveque E, Casanovas N, Kamphuis JBJ, Creeks P, Romero J, Sohail S, et al. Widespread monoclonal IgE antibody convergence to an immunodominant, proanaphylactic Ara h 2 epitope in peanut allergy. J Allergy Clin Immunol. 2024 Jan;153(1):182-192.e7.
- Ota M, et al. CD23+IgG1+ memory B cells are poised to switch to pathogenic IgE production in food allergy. Sci Transl Med. 2024 Feb 7;16(733):eadi0673.